Plakin Expression in Serous Epithelial Ovarian Cancer Has the Potential to Impede Metastatic Spread and Epithelial-Mesenchymal Transition: A Comparative Expression Analysis of Immunohistochemical and In Silico Datasets

• Journals
• DOI reference: 10.3390/cancers16234087

In Vitro and In Silico Analysis of Epithelial-Mesenchymal Transition and Cancer Stemness as Prognostic Markers of Clear Cell Renal Cell Carcinoma

• Journals
• DOI reference: 10.3390/cancers15092586

Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial–mesenchymal transition interlinked with reprogrammed metabolism

• Journals
• DOI reference: 10.1186/s12967-022-03776-y

Knock down of TIMP-2 by siRNA and CRISPR/Cas9 mediates diverse cellular reprogramming of metastasis and chemosensitivity in ovarian cancer

• Journals
• DOI reference: 10.1186/s12935-022-02838-x

Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma

• Journals
• DOI reference: 10.3389/fmed.2022.766869

Expression of TIMPs and MMPs in Ovarian Tumors, Ascites, Ascites-Derived Cells, and Cancer Cell Lines: Characteristic Modulatory Response Before and After Chemotherapy Treatment

• Journals
• DOI reference: 10.3389/fonc.2021.796588

The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence

• Journals
• DOI reference: 10.1186/s12964-021-00726-x

Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma

• Journals
• DOI reference: 10.1186/s13046-021-01961-3

In Vitro and in Vivo Toxicity and Biodistribution of Paclitaxel-Loaded Cubosomes as a Drug Delivery Nanocarrier: A Case Study Using an A431 Skin Cancer Xenograft Model

• Journals
• DOI reference: 10.1021/acsabm.0c00269

TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells

• Journals
• DOI reference: 10.1186/s12885-020-07274-6

Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods

• Journals
• DOI reference: 10.3390/cells9030719

Paclitaxel-induced src activation is inhibited by dasatinib treatment, independently of cancer stem cell properties, in a mouse model of ovarian cancer

• Journals
• DOI reference: 10.3390/cancers11020243

Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells

• Journals
• DOI reference: 10.1016/j.semcancer.2018.10.002

Paclitaxel-Loaded Self-Assembled Lipid Nanoparticles as Targeted Drug Delivery Systems for the Treatment of Aggressive Ovarian Cancer

• Journals
• DOI reference: 10.1021/acsami.8b08125

Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer

• Journals
• DOI reference: 10.18632/oncotarget.24615

The many facets of metzincins and their endogenous inhibitors: Perspectives on ovarian cancer progression

• Journals
• DOI reference: 10.3390/ijms19020450

Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling

• Journals
• DOI reference: 10.1038/srep46312

Surface profiling of extracellular vesicles from plasma or ascites fluid using DotScan antibody microarrays

• Book Chapters
• DOI reference: 10.1007/978-1-4939-7057-5_20

Coalition of Oct4A and beta 1 integrins in facilitating metastasis in ovarian cancer

• Journals
• DOI reference: 10.1186/s12885-016-2458-z

Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells

• Journals
• DOI reference: 10.1038/srep30061